Adjuvant therapy for pancreas adenocarcinoma: Where are we going?

Expert Review of Anticancer Therapy

Volumn 11, Issue 2, 2011, Pages 173-177

  O'Reilly, Eileen M ^a  

^a Gastrointestinal Oncology Service   (United States)

Author keywords

5 fluororuacil; adjuvant therapy; gemcitabine; leucovorin; pancreas

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GEMCITABINE;

ADJUVANT THERAPY; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SCREENING; DIARRHEA; DISEASE FREE SURVIVAL; HUMAN; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PATIENT SELECTION; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; TREATMENT DURATION;

EID: 79952128451     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.232     Document Type: Review

References (30)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J. Clin. 60(5), 277-300 (2010).
2. Ferrone CR, Brennan MF, Gonen M et al. Pancreatic adenocarcinoma: the actual 5-year survivors. J. Gastrointest. Surg. 12(4), 701-706 (2008). • Describes the clinical characteristics of actuarial 5-year survivors of patients who underwent a curative resection for pancreas adenocarcinoma. Predictably, the American Joint Committee on Cancer (AJCC) stage of disease and negative lymph nodes were predictors of long-term outcome.
3. Chua YJ, Cunningham D. Adjuvant treatment for resectable pancreatic cancer. J. Clin. Oncol. 23(20), 4532-4537 (2005).
4. Nugent FW, Stuart K. Adjuvant and neoadjuvant therapy in curable pancreatic cancer. Surg. Clin. North Am. 90(2), 323-339 (2010).
5. Sohn TA, Yeo CJ, Cameron JL et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J. Gastrointest. Surg. 4(6), 567-579 (2000).
6. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch. Surg. 120(8), 899-903 (1985).
7. Regine WF, Winter KA, Abrams RA et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 299(9), 1019-1026 (2008). • • This Phase III trial evaluates adjuvant gemcitabine compared with infusional 5-fluorouracil in resected pancreas adenocarcinoma in patients. It is only the second fully reported randomized adjuvant trial in pancreas adenocarcinoma patients in the USA.
8. Klinkenbijl JH, Jeekel J, Sahmoud T et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann. Surg. 230(6), 776-782; discussion 782-784 (1999).
9. Neoptolemos JP, Dunn JA, Stocken DD et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 358(9293), 1576-1585 (2001).
10. Neoptolemos JP, Stocken DD, Friess H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. 350(12), 1200-1210 (2004). •• The European Study Group for Pancreas Cancer (ESPAC)-1 study in a complex statistical design, concludes that adjuvant 5-flurouracil and leucovorin offers a survival advantage over observation in resected pancreas adenocarcinoma patients and that combined chemoradiation does not add benefit. The results and interpretation have been heavily critiqued. Regardless, the results of this trial provided a major move away from the routine use of combined chemoradiation in the adjuvant setting in Europe.
11. Abrams RA, Lillemoe KD, Piantadosi S. Continuing controversy over adjuvant therapy of pancreatic cancer. Lancet 358(9293), 1565-1566 (2001).
12. Choti MA. Adjuvant therapy for pancreatic cancer - the debate continues. N. Engl. J. Med. 350(12), 1249-1251 (2004).
13. Evans DB, Hess KR, Pisters PW. ESPAC-1 trial of adjuvant therapy for resectable adenocarcinoma of the pancreas. Ann. Surg. 236(5), 694; author reply 694-696 (2002).
14. Oettle H, Post S, Neuhaus P et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297(3), 267-277 (2007).
15. Neuhaus P, Riess H, Post S et al. CONKO-001: final results of the randomized, prospective, multicenter Phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). J. Clin. Oncol. (Meeting Abstracts) 26(15 Suppl.), LBA4504 (2008). •• Although the initial report of the Charité Onkologie Clinical (CONKO)-001 trial did not demonstrate an overall survival benefit from gemcitabine treatment, the updated report herein did and firmly establishes gemcitabine as an adjuvant therapy option.
16. Neoptolemos JP, Stocken DD, Bassi C et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304(10), 1073-1081 (2010).
17. O'Reilly EM. Refinement of adjuvant therapy for pancreatic cancer. JAMA 304(10), 1124-1125 (2010).
18. Twombly R. Adjuvant chemoradiation for pancreatic cancer: few good data, much debate. J. Natl Cancer Inst. 100(23), 1670-1671 (2008).
19. Backlund DC, Berlin JD, Parikh AA. Update on adjuvant trials for pancreatic cancer. Surg. Oncol. Clin. N. Am. 19(2), 391-409 (2010).
20. Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 7(4), e1000267 (2010). •• This rigorous meta-analysis provides the most comprehensive summary of preoperative trials conducted in pancreas adenocarcinoma. The results are derived from 56 mostly Phase I-II single-institution studies. Overall, it supports the further evaluation of preoperative therapy, particularly in the borderline resectable population.
21. Abbott DE, Baker MS, Talamonti MS. Neoadjuvant therapy for pancreatic cancer: a current review. J. Surg. Oncol. 101(4), 315-320 (2010).
22. Varadhachary GR, Tamm EP, Abbruzzese JL et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann. Surg. Oncol. 13(8), 1035-1046 (2006).
23. Lal A, Christians K, Evans DB. Management of borderline resectable pancreatic cancer. Surg. Oncol. Clin. N. Am. 19(2), 359-370 (2010).
24. Lowy AM. Neoadjuvant therapy for pancreatic cancer. J. Gastrointest. Surg. 12(9), 1600-1608 (2008).
25. Abrams RA, Lowy AM, O'Reilly EM, Wolff RA, Picozzi VJ, Pisters PW. Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann. Surg. Oncol. 16(7), 1751-1756 (2009). •• This position paper reports on a consensus conference reviewing definitions pertaining to resectable, borderline resectable pancreas adenocarcinoma along with the rationale for adjuvant therapy and neoadjuvant therapy as well as pointers for clinical trial design in these patient populations.
26. Yachida S, Jones S, Bozic I et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467(7319), 1114-1117 (2010). •• Reports on the sequencing of several pancreas cancer genomes and describes the natural history of the development of pancreas adenocarcinoma, and suggests that the development of clinically detectable pancreas adenocarcinoma may be preceded by several decades of a preinvasive state. Possible implications may relate to screening and early detection.
27. Buchholz M, Gress TM. Molecular changes in pancreatic cancer. Expert Rev. Anticancer Ther. 9(10), 1487-1497 (2009).
28. Jones S, Zhang X, Parsons DW et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321(5897), 1801-1806 (2008). •• Following a comprehensive analysis of 24 human pancreas cancer genomes, the observations that approximately 63 genetic alterations occur in pancreas cancer (mostly point mutations) and that approximately 12 key signaling pathways are affected, were drawn. Future application of this information may pertain to targeting multiple pathways that are integral to the pathogenesis of pancreas adenocarcinoma.
29. Klapman J, Malafa MP. Early detection of pancreatic cancer: why, who, and how to screen. Cancer Control 15(4), 280-287 (2008).
30. Campbell PJ, Yachida S, Mudie LJ et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467(7319), 1109-1113 (2010).